Subgroup analysis of patients treated with FOLFIRINOX revealed a longer PFS with losartan than control but did not reach statistical significance, likely due to small sample size.
← all excerpts
Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy.
1
—
—